Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA looks at calcium salt bone void filler:

This article was originally published in Clinica

Executive Summary

The US FDA has proposed to classify resorbable calcium salt bone void filler used to fill bony voids or gaps caused by trauma or surgery into class II special controls (a guidance document has been released at the same time). The reclassification applies to those fillers that are not intrinsic to the stability of the bony structure. The product was on the market prior to 1976 when the amendments to US Food and Drug law establishing medical device regulation went into effect and therefore was allowed to remain on the market until it could be classified by the agency. The FDA inadvertently left the product off the list when it classified other pre-amendment products in 1987. Comments are due on May 8.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064771

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel